Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene

Human Gene Therapy

Volumn 7, Issue 6, 1996, Pages 773-792

  Chang, Alfred E ^a   Sondak, Vernon K ^a   Bishop, D Keith ^a   Nickoloff, Brian J ^a   Mulligan, Richard C ^a,b,c   Mulé, James J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

^c CELL GENESYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; OKT 3; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; IMMUNE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; LYMPH NODE CELL; MELANOMA; PATIENT SELECTION; REVIEW; T LYMPHOCYTE; TUMOR CELL;

EID: 0029868425     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1996.7.6-773     Document Type: Review

References (27)

1. Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: Association with clinical response. J. Natl. Cancer Inst. 1991; 83:932-937.
2. Chang AE, Shu S. Immunotherapy with sensitized lymphocytes. Canc. Invest. 1992; 10:357-369.
3. Shu S, Chou T, and Rosenberg SA. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 1987; 139:295-304.
4. Chou T, Chang AE, and Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization. J. Immunol. 1988; 140:2453-2461.
5. Chou T, Bertera S, Chang AE, and Shu S. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors. J. Immunol. 1988; 141:1775-1781.
6. Shu S, Chou T, and Sekai K. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J. Immunol. 1989; 143:740-748.
7. Sakai K, Chang AE, and Shu S. Effector phenotype and immunologic specificity of T cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cell. Immunol. 1990; 129:241-255.
8. Yoshizawa H, Chang AE, and Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J. Immunol. 1991; 147:729-737.
9. Yoshizawa H, Sakai K, Chang AE, and Shu S. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 1991; 134:473-479.
10. Yoshizawa H, Chang AE, and Shu S. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin-2 activated tumor-draining lymph node cells. Canc. Res. 1992; 52:1129-1136.
11. Leo O, Foo M, Sachs DH, et al. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc. Natl. Acad. Sci. 1987; 84:1374-1378.
12. Ting C-C, Hargrove ME, and Yun YS. Augmentation by anti-T3 antibody of the lymphokine-activated killer cell mediated cytotoximy. J. Immunol. 1988; 141:741-748.
13. Anderson PM, Blazar BR, Bach FH, and Ochoa AC. Anti-CD3 + IL-2 stimulated murine killer cells. In vitro generation and in vivo antitumor activity. J. Immunol. 1989; 142:1383-1394.
14. Geiger JD, Wagner PD, Cameron MJ, et al. Generation of T cells reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother. 1993; 13:153-165.
15. Geiger JD, Wagner PD, Shu S, and Chang AE. A novel role for autologous tumor cell vaccination in the immunotherapy of the poorly immunogenic B16-BL6 melanoma. Surg. Onc. 1992; 1: 199-208.
16. Chang AE, Yoshizawa H, Sakai K, et al. Clinical observations on adoptive immunotherapy with vaccine-primed T lymphocytes secondarily sensitized to tumor in vitro. Canc. Res. 1993; 53: 1043-1050.
17. Berd D, Maguire HC, McCue P, and Mastrangelo MJ. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J. Clin. Oncol. 1990; 8:1858-1867.
18. Hoover HC, Brandhorst JS, Peters LC, et al. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5 year median follow-up of a phase III prospective randomized trial. J. Clin. Oncol. 1993; 11:390-399.
19. Chang AE, Cameron MJ, Fox BA, and Shu S. Generation of anti-CD3/IL-2 activated, vaccine-primed lymph node cells for the adoptive immunotherapy of human malignancy. (Abst. 2924) Proc. Am. Assoc. Cancer Res. 1993; 34:490.
20. Fearon ER, Pardoll DM, Itaya T, et al. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60:397-403.
21. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254:713-716.
22. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992; 257:548-551.
23. Strome SE, Krauss JC, Cameron MJ, et al. Immunobiologic effects of cytokine gene transfer of the B16-BL6 melanoma. Arch. of Otol. 119:1289-1295, 1993.
24. Dranoff G, Jaffee E, Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. 1993; 90:3539-3543.
25. Danos O, and Mulligan RC. Safe and efficient generation of recombinant retroviruses with amphotropic and ecotropic host ranges. Proc. Natl. Acad. Sci. 1988; 85:6460-6464.
26. Kleinerman ES, Knowles RD, Lachman LB, Gutterman JU. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res. 48:2604-2609, 1988.
27. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. NEJM 318:869-876, 1988.